
An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.
Debilitating pain-affecting millions of Americans-was often alleviated by traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors. But the appeal of these once-popular drugs is declining due to safety concerns.






